Changes in Beneficial Ownership · 4

Rapport Therapeutics, Inc.

RAPPNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Oct 30, 2026Accepted Oct 30, 2026, 7:32 PM EDTFiling CIK 2012593Accession 0001104659-26-120789

View company →Permanent SEC source ↗

Structured filing — 4

tm2628672-1_4seq1.xml

Open full document ↗

Filing details

Report period: 2026-10-28
Issuer: Rapport Therapeutics, Inc.
Issuer CIK: 0002012593
Trading symbol: RAPP

Reporting owner 1

Name: HEALY JAMES
Reporting owner CIK: 0001245624
Relationship: Director
Address: SOFINNOVA INVESTMENTS, INC., 3000 SAND HILL ROAD, BLDG. 3, SUITE 150, MENLO PARK, CA, 94025

Non-derivative transactions

Non-derivative transactions · 4 reported rows
Security	Transaction date	Code	Amount	A / D	Price (USD)	Owned after	Ownership	Nature of ownership
Common Stock	2026-10-28	P · Form 4	952,380	A	21.00	2,815,707	I	By Sofinnova Venture Partners XI, L.P.^[F1]
Common Stock	2026-10-28	P · Form 4	6,395	A	21.00	17,990	I	By SummitTX Master, SPC -SummitTX Apex SP - Healthcare 3^[F2]
Common Stock	2026-10-28	P · Form 4	3,772	A	21.00	14,924	I	By SummitTX Master, SPC - SummitTX Alpha SP - Healthcare 3^[F3]
Common Stock	2026-10-28	P · Form 4	6,933	A	21.00	25,267	I	By SummitTX Pinnacle Master, L.P. - Healthcare 3^[F4]

Table key

P · Form 4: Purchase on the market or privately
A: Acquired
I: Indirect

Footnotes

F1: The shares are directly held by Sofinnova Venture Partners XI, L.P. ("SVP XI"). Sofinnova Management XI, L.P. ("SM XI LP") is the general partner of SVP XI and Sofinnova Management XI, L.L.C. ("SM XI") is the general partner of SM XI LP. The Reporting Person is a managing member of SM XI and may be deemed to share voting and dispositive power over the shares held by SVP XI. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.↩ 1
F2: The shares are directly held by SummitTX Master, SPC - SummitTX Apex SP - Healthcare 3 (f/k/a Crestline Summit Master, SPC - Crestline Summit Apex SP) ("Apex SP"). Sofinnova BioEquities GP LLC ("BioEquities GP") is the general partner of Apex SP. The Reporting Person is a managing member of BioEquities GP and may be deemed to share voting and dispositive power over the shares held by Apex SP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.↩ 1
F3: The shares are directly held by SummitTX Master, SPC - SummitTX Alpha SP - Healthcare 3 (f/k/a Crestline Summit Master, SPC - PEAK SP) ("Alpha SP"). BioEquities GP is the general partner of Alpha SP. The Reporting Person is a managing member of BioEquities GP and may be deemed to share voting and dispositive power over the shares held by Alpha SP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.↩ 1
F4: The shares are directly held by SummitTX Pinnacle Master, L.P. - Healthcare 3 (f/k/a Crestline Summit Pinnacle Master, L.P.) ("Pinnacle LP"). BioEquities GP is the general partner of Pinnacle LP. The Reporting Person is a managing member of BioEquities GP and may be deemed to share voting and dispositive power over the shares held by Pinnacle LP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.↩ 1

Signature 1

Signed: /s/ Nathalie Auber, Attorney-in-Fact
Date: 2026-10-30

Company context

Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological and psychiatric disorders. The Company’s founders made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain, which form the basis of Rapport’s RAP technology platform. The platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, which is designed to achieve neuroanatomical specificity through selective targeting of a RAP expressed only in discrete regions of the brain. The pipeline is anchored by the Company’s epilepsy portfolio, including FOS and primary generalized tonic-clonic seizures, as well as bipolar mania. The Company is also advancing additional discovery and preclinical programs leveraging its platform, including in chronic pain and migraine and in hearing and vestibular disorders.

Current securities

RAPPNASDAQ · EQUITY · Current

Get the free weekly BCS email.